Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

What's the impact of mixing lipitor bp meds negatively?
The expiration date of the key patent for guselkumab?
Norcuron generic name?
When does guselkumab patent expire?
What are the most memorable drug brands in oral factor b inhibitors? in united states

Can you take lyrica with hydrocodone?

See the DrugPatentWatch profile for lyrica

Is it safe to take Lyrica (pregabalin) with hydrocodone?

Using pregabalin (Lyrica) together with hydrocodone can be risky because both can depress the central nervous system. That combination can increase the chance of serious side effects such as extreme sleepiness, slowed breathing, and impaired thinking or coordination. Because of this, they are often treated as a “use caution/avoid unless necessary” pairing, especially when doses are higher or other sedating medicines are involved.[1]

What side effects should you watch for?

People who take this combination may experience enhanced opioid/sedative effects, including:
- Strong drowsiness or difficulty staying awake
- Dizziness, confusion, or trouble concentrating
- Poor coordination, increased fall risk
- Slow or shallow breathing, which is an emergency symptom
If you notice breathing problems, severe unresponsiveness, or you cannot easily wake the person up, seek emergency help immediately.[1]

Who is at higher risk of complications?

Risk is higher when hydrocodone is combined with other medications or substances that also slow breathing or increase sedation, such as benzodiazepines (for anxiety/sleep), alcohol, or other opioids. Risk is also higher if you have underlying lung disease or sleep apnea.[1]

What should you do if both are prescribed?

If a clinician prescribed both together, follow the exact directions and avoid alcohol and other sedatives. Do not increase doses without medical advice. If you feel unusually sleepy or notice breathing changes, contact the prescriber promptly; the combination may need dose adjustment or an alternative treatment.[1]

Can they be taken together for short periods?

Short-term use can still cause dangerous sedation or breathing suppression, especially at the start of therapy, after dose changes, or if you take other sedating substances. The safest approach is to only take them together if your prescriber specifically instructed you to, with careful monitoring for sedation and breathing symptoms.[1]

Alternatives or next steps to ask your clinician about

If your goal is pain control while minimizing sedation risk, your clinician may consider adjusting either therapy (dose/timing) or switching to different options that don’t stack respiratory and sedative effects as strongly.[1]

Sources
[1] FDA Drug Safety Communication: Serious risks and death can occur when gabapentinoids (including pregabalin/Lyrica) are used with opioids; requires label changes and warnings (2020). https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-label-changes-gabapentinoids-about-serious-breathing-problems-using-opioids

Prescribing Information Alignment Report

Executive Summary

Overall Alignment: Unable to Assess

The provided FDA-approved pregabalin (LYRICA) labeling excerpt supports several safety concepts about respiratory depression and additive CNS effects with opioids/CNS depressants. However, the specific AI claims include many granular details (e.g., exact symptom lists, “use caution/avoid unless necessary” framing, timing “especially high at start/after dose changes,” and risk factors such as sleep apnea) that are not fully verifiable from the supplied label text. As a result, alignment cannot be fully determined for the complete set of claims.

Alignment Scorecard

Category	Status	Notes
Indication	Not Applicable	No indication-related AI claims evaluated against Section 1.
Patient Population	Unable to Assess	Claims reference conditions (e.g., underlying lung disease, sleep apnea) not specifically substantiated in the provided excerpt.
Dosage & Administration	Unable to Assess	Timing/dose-change statements are not present in the excerpt (e.g., “especially high after dose changes”).
Contraindications	Not Addressed	No contraindication claims about this combination were provided.
Warnings & Precautions	Partially Aligned	Respiratory depression warning when co-administered with CNS depressants including opioids is supported; several finer details are not verifiable from the excerpt.
Drug Interactions	Partially Aligned	Additive effects on cognitive/gross motor functioning with co-administration with lorazepam/ethanol/oxycodone are supported, but opioid-specific hydrocodone and detailed “enhanced opioid/sedative effects” symptom lists are not fully supported.
Adverse Reactions	Partially Aligned	Dizziness and somnolence are supported; other listed adverse effects (e.g., confusion/trouble concentrating/fall risk) are not explicitly supported in the provided excerpt.
Monitoring	Partially Aligned	Label supports monitoring for symptoms of respiratory depression and sedation when co-prescribing with CNS depressants, including opioids; “emergency symptom” wording is not directly present.
Administration Instructions	Partially Aligned	Label supports considering low-dose initiation when co-prescribing with CNS depressants/opioids and underlying respiratory impairment; specific initiation timing claims are not provided.
Limitations of Use	Not Addressed	No “avoid unless necessary” or limitations-of-use language is provided in the excerpt.
Special Populations	Unable to Assess	Risk mentions for sleep apnea/underlying lung disease are not specifically included in the provided excerpt.

Key Findings

Supported: Co-administration with CNS depressants including opioids is associated with serious/life-threatening/fatal respiratory depression; label advises monitoring for respiratory depression/sedation and considering low-dose initiation.
Supported: Pregabalin may cause dizziness and somnolence; onset shortly after initiation and more frequent at higher doses is stated.
Partially supported: Additive effects on cognitive and gross motor functioning with co-administration of pregabalin and CNS depressants (including oxycodone, lorazepam, ethanol) are supported; however, detailed symptom lists and “hydrocodone” specificity are not fully verifiable from the excerpt.
Unable to Assess: Claims about “use caution/avoid unless necessary,” specific timing after dose changes, fall risk, confusion/trouble concentrating, and risk modulation by sleep apnea/underlying lung disease are not fully supported by the provided labeling text.

Claim-by-Claim Assessment

AI Claim	Assessment	Supporting Evidence	Potential Impact
Using pregabalin (Lyrica) together with hydrocodone can be risky because both can depress the central nervous system.	Partially Supported	Label states serious respiratory depression when co-administered with CNS depressants, including opioids; provided excerpt does not specifically mention hydrocodone.	High
The combination of pregabalin and hydrocodone can increase the chance of serious side effects such as extreme sleepiness.	Partially Supported	Label supports sedation/somnolence and recommends monitoring for sedation with CNS depressants/opioids; “extreme” sleepiness not directly worded.	Moderate
The combination of pregabalin and hydrocodone can increase the chance of serious side effects such as slowed breathing.	Supported	Respiratory depression (serious/life-threatening/fatal) associated with co-administration with CNS depressants including opioids.	High
The combination of pregabalin and hydrocodone can increase the chance of serious side effects such as impaired thinking or coordination.	Partially Supported	Label drug interaction section: additive effects on cognitive and gross motor functioning when co-administered with oxycodone/lorazepam/ethanol; excerpt does not explicitly mention hydrocodone.	Moderate
Pregabalin and hydrocodone are often treated as a 'use caution/avoid unless necessary' pairing.	Not Addressed	“Use caution/avoid unless necessary” framing is not present in the provided labeling excerpt.	Informational
Enhanced opioid/sedative effects may occur with the combination of pregabalin and hydrocodone.	Partially Supported	Label warns to monitor for symptoms of respiratory depression and sedation when co-prescribing with CNS depressants, including opioids; “enhanced opioid effects” terminology not exact.	Moderate
Enhanced opioid/sedative effects include strong drowsiness or difficulty staying awake.	Partially Supported	Somnolence is listed as an adverse effect of LYRICA; label advises monitoring for sedation with opioids.	Moderate
Enhanced opioid/sedative effects include dizziness.	Supported	LYRICA may cause dizziness; label provides incidence in trials and counseling regarding impairment.	Informational
Enhanced opioid/sedative effects include confusion.	Not Addressed	Confusion is not explicitly stated in the provided excerpt.	Informational
Enhanced opioid/sedative effects include trouble concentrating.	Not Addressed	Trouble concentrating is not explicitly stated; only general cognitive/gross motor additive effects are described.	Informational
Enhanced opioid/sedative effects include poor coordination.	Partially Supported	Additive effects on gross motor functioning are described; “poor coordination” not explicitly worded.	Moderate
Enhanced opioid/sedative effects include increased fall risk.	Not Addressed	Fall risk is not mentioned in the provided excerpt.	Informational
Slow or shallow breathing can occur with the combination and is an emergency symptom.	Partially Supported	Respiratory depression is described; however, the excerpt does not explicitly use “slow or shallow breathing” or label it as an emergency symptom.	High
The risk of complications is higher when hydrocodone is combined with other medications or substances that also slow breathing or increase sedation.	Supported	Label associates serious/fatal respiratory depression with CNS depressants including opioids and underlying respiratory impairment; additive CNS depressant risk is consistent with label guidance (monitoring).	High
The risk of complications is higher with benzodiazepines used with hydrocodone and pregabalin.	Partially Supported	Label interaction study includes co-administration with lorazepam (a benzodiazepine) showing additive cognitive/gross motor effects; the respiratory-depression risk text is general to CNS depressants including opioids, not benzodiazepines specifically for the combination.	Moderate
The risk of complications is higher with alcohol used with hydrocodone and pregabalin.	Partially Supported	Label drug interactions section: additive effects on cognitive and gross motor functioning with ethanol; increased “complication” risk magnitude not quantified in excerpt.	Moderate
The risk of complications is higher with other opioids used with hydrocodone and pregabalin.	Cannot Determine	Provided excerpt addresses co-prescribing pregabalin with CNS depressants including opioids, but does not address “other opioids” in addition to hydrocodone or stacking multiple opioids.	Informational
The risk of complications is higher if the person has underlying lung disease.	Supported	Respiratory depression evidence includes setting of underlying respiratory impairment; underlying lung disease is a form of respiratory impairment (consistent but not explicitly named).	High
The risk of complications is higher if the person has sleep apnea.	Cannot Determine	Sleep apnea is not mentioned in the provided excerpt; only “underlying respiratory impairment” is referenced.	Informational
Short-term use of pregabalin with hydrocodone can still cause dangerous sedation or breathing suppression.	Partially Supported	Label supports serious respiratory depression with CNS depressants including opioids and notes dizziness/somnolence may begin shortly after initiation; it does not specifically address “short-term” with hydrocodone.	High
The risk of dangerous sedation or breathing suppression is especially high at the start of therapy.	Partially Supported	Label states dizziness/somnolence generally began shortly after initiation; respiratory depression timing “especially high at the start” is not specified.	Moderate
The risk of dangerous sedation or breathing suppression is especially high after dose changes.	Not Addressed	The excerpt does not state respiratory depression risk is especially high after dose changes.	Informational
The risk of dangerous sedation or breathing suppression is especially high if other sedating substances are taken.	Supported	Label associates serious respiratory depression with CNS depressants including opioids and advises monitoring when co-prescribing with CNS depressants, implying risk with additional sedating CNS depressants.	High
The FDA has stated that serious risks and death can occur when gabapentinoids, including pregabalin (Lyrica), are used with opioids.	Partially Supported	Label excerpt states evidence associating pregabalin with serious, life-threatening, or fatal respiratory depression when co-administered with CNS depressants including opioids.	High
The FDA required label changes and warnings about serious breathing problems when gabapentinoids are used with opioids.	Cannot Determine	Whether the FDA “required label changes” is not stated in the provided excerpt.	Informational

Important Omissions

No AI claim assessment provided coverage for key LYRICA topics in the excerpt such as contraindications (hypersensitivity), tapering/discontinuation effects, or other warnings (e.g., peripheral edema, weight gain, tumorigenic potential).
No assessment of pregabalin-specific dosing/renal adjustment language, which is present in the provided label excerpt.

Unsupported / Hallucinated Content

Confusion as an effect of the combination (not explicitly present in the provided excerpt).
Trouble concentrating as a specific listed adverse effect (not explicitly present in the provided excerpt).
Fall risk as a specific adverse effect (not explicitly present in the provided excerpt).
Sleep apnea as a specific risk factor (not explicitly present in the provided excerpt).
FDA-required label changes statement (not supported from the provided excerpt text).

Potential Patient Safety Concerns

Several AI claims align with label warnings that co-administration with opioids/CNS depressants can be associated with serious, life-threatening, or fatal respiratory depression. However, unverified or overly specific statements (e.g., “emergency symptom” framing, timing after dose changes, fall risk, sleep apnea) could mislead users about the precision and scope of risk; these elements are not fully corroborated by the supplied labeling excerpt.

Overall Assessment

The AI response captures core safety concepts from the provided LYRICA labeling excerpt: co-administration with CNS depressants including opioids is associated with serious/fatal respiratory depression, and LYRICA can cause dizziness and somnolence with monitoring advised when used with CNS depressants. Alignment is reduced for claims that add granular symptom lists, specific risk-factor conditions (e.g., sleep apnea), and operational timing (“especially high” at start/after dose changes), which are not explicitly supported in the provided label text. The FDA label-change framing is also not determinable from the excerpt.

Brand Assessment

GEO Score

Visibility

Mentioned

Ranking

Sentiment

Recommendation Status

discouraged

Brand Perception

Best Known For

pregabalin (Lyrica)

Core Claims

Using pregabalin (Lyrica) together with hydrocodone can be risky
Both can depress the central nervous system
The combination can increase the chance of serious side effects
Serious side effects include extreme sleepiness, slowed breathing, and impaired thinking or coordination

Differentiators

Framed as a 'use caution/avoid unless necessary' pairing with hydrocodone
Specifically linked to risk of respiratory depression when combined with opioids

Pricing Perception: Not Mentioned

Competitors Mentioned

Company	Visibility	Sentiment	Rank	Recommended
Benzodiazepines	26%	30	#3	No
Alcohol	12%	20	#4	No
Opioids	27%	25	#5	No

Potential Risks

Critical